ZFIN ID: ZDB-FISH-150901-12102
Fish name: lama2teg15a/teg15a
Genotype: lama2teg15a/teg15a
Targeting Reagent: none
HUMAN DISEASE MODELED by lama2teg15a/teg15a
Human Disease Conditions Citations
muscular dystrophy control Li et al., 2015
congenital merosin-deficient muscular dystrophy 1A standard conditions (2)
GENE EXPRESSION
Gene expression in lama2teg15a/teg15a
Reporter gene expression No data available
PHENOTYPE
Phenotype in lama2teg15a/teg15a
Phenotype Conditions Figures
apoptotic process delayed, abnormal control Fig. 4 from Sztal et al., 2012
fast muscle cell detached from myoseptum, abnormal standard conditions Fig. 2 from Sztal et al., 2012
larval locomotory behavior decreased rate, abnormal standard conditions Table 1 from Granato et al., 1996
muscle damaged, abnormal standard conditions Fig. 1 from Sztal et al., 2012
muscle dystrophic, abnormal standard conditions Fig. 1 from Sztal et al., 2012
muscle refractivity, abnormal standard conditions Fig. 2 with image from Smith et al., 2017
muscle organ development disrupted, abnormal standard conditions Fig. 1 with image,  Fig. 3 with image from Hall et al., 2007
musculoskeletal movement decreased magnitude, abnormal standard conditions Fig. 1 with image from Smith et al., 2017
myotome degenerate, abnormal standard conditions Table 1 from Granato et al., 1996
myotome morphology, abnormal standard conditions Fig. 7 from Wood et al., 2018
Fig. 4 from Sztal et al., 2012
myotome refractivity, abnormal standard conditions Fig. 1,  Fig. 3,  Fig. 4 from Sztal et al., 2012
Table 1 from Granato et al., 1996
myotome structure, abnormal standard conditions Fig. 1 with image,  Fig. 3 with image from Hall et al., 2007
myotome extracellular matrix structure, abnormal standard conditions Fig. 4 with image from Hall et al., 2007
myotome sarcolemma structure, normal standard conditions Fig. 2 with image from Hall et al., 2007
myotome skeletal muscle cell decreased amount, abnormal standard conditions Fig. 1 with image from Jacoby et al., 2009
myotome skeletal muscle cell degeneration, abnormal standard conditions Fig. 1 with image from Jacoby et al., 2009
skeletal muscle decreased strength, abnormal chemical treatment: toluene-4-sulfonamide Fig. 4 with image,  Fig. 5 with image from Li et al., 2015
skeletal muscle decreased strength, abnormal control Fig. 4 with image,  Fig. 5 with image from Li et al., 2015
skeletal muscle deformed, abnormal chemical treatment: toluene-4-sulfonamide Fig. 2 with image from Li et al., 2015
skeletal muscle disorganized, abnormal control Fig. 2 with image from Li et al., 2015
skeletal muscle disorganized, abnormal chemical treatment: toluene-4-sulfonamide Fig. 5 with image from Li et al., 2015
skeletal muscle disorganized, ameliorated chemical treatment: toluene-4-sulfonamide Fig. 2 with image from Li et al., 2015
skeletal muscle structure, abnormal control Fig. 2 with image,  Fig. 3 with image from Li et al., 2015
skeletal muscle structure, ameliorated chemical treatment: toluene-4-sulfonamide Fig. 2 with image,  Fig. 3 with image from Li et al., 2015
skeletal muscle cell alignment skeletal muscle, abnormal chemical treatment: toluene-4-sulfonamide Fig. 2 with image from Li et al., 2015
skeletal muscle cell apoptotic, abnormal control Fig. 4 from Sztal et al., 2012
skeletal muscle cell detached from vertical myoseptum, abnormal standard conditions Fig. 1 with image,  Fig. 4 with image from Hall et al., 2007
skeletal muscle cell detached from myoseptum, abnormal standard conditions Fig. 1 from Sztal et al., 2012
skeletal muscle cell disorganized, abnormal control Fig. 2 with image from Li et al., 2015
skeletal muscle cell dystrophic, abnormal standard conditions Fig. 1 with image from Hall et al., 2007
skeletal muscle cell retracted, abnormal standard conditions Fig. 1 with image,  Fig. 4 with image from Hall et al., 2007
skeletal muscle cell undulate, abnormal chemical treatment: toluene-4-sulfonamide Fig. 2 with image from Li et al., 2015
skeletal muscle cell filamentous actin aggregated, abnormal standard conditions Fig. 5 with image from Smith et al., 2017
slow muscle cell detached from myoseptum, abnormal standard conditions Fig. 2,  Fig. 3,  Fig. 4 from Sztal et al., 2012
somite muscle cell detached from somite, abnormal standard conditions Fig. 2 with image from Smith et al., 2017
thigmotaxis decreased rate, abnormal standard conditions Table 1 from Granato et al., 1996
thigmotaxis disrupted, abnormal standard conditions Fig. 1 with image from Smith et al., 2017
trunk musculature degenerate, abnormal standard conditions Fig. 2 with image from Smith et al., 2017
vertical myoseptum col1a1a expression decreased amount, abnormal standard conditions Fig. 7 from Wood et al., 2018
vertical myoseptum deformed, abnormal standard conditions Fig. 5 with image from Hall et al., 2007
whole organism immobile, abnormal chemical treatment: toluene-4-sulfonamide text only from Li et al., 2015
whole organism neuromuscular junction structure, normal standard conditions Fig. 8 with image from Hall et al., 2007

CITATIONS  (9)

Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.